Financial Performance - Total revenues for the first nine months of 2024 were approximately $6.9 million, an increase of 35.3% from approximately $5.1 million in the same period of 2023[11]. - Revenues for Q3 2024 were approximately $1.8 million, a decrease of 52.6% compared to approximately $3.8 million in Q3 2023, primarily due to a $2.5 million licensing fee recognized in Q3 2023[5]. - The net loss for the first nine months of 2024 was approximately $18.0 million, a slight improvement from a net loss of approximately $18.6 million in the same period of the previous year[60]. - The net loss for the third quarter of 2024 was approximately $8.2 million, compared to approximately $3.9 million in the same period of the previous year, indicating a $4.3 million increase in net loss due to decreased revenues and increased expenses[60]. - Gross profit for the nine months ended September 30, 2024, was $4,972,000, compared to $3,768,000 in the same period of 2023, indicating a gross profit margin improvement[78]. - The basic and diluted loss per share attributable to equity holders of the company for the nine months ended September 30, 2024, was $(3.17), compared to $(3.91) for the same period in 2023[78]. Expenses and Liabilities - General and administrative expenses for the first nine months of 2024 increased to approximately $6.1 million from approximately $4.8 million in the same period of 2023[30]. - Financing expenses, net for the first nine months of 2024 were approximately $0.38 million, compared to financing income of approximately $0.23 million in the same period of 2023[35]. - Operating loss for the first nine months of 2024 was approximately $17.6 million, a decrease from approximately $18.9 million in the same period of 2023[55]. - Research and development expenses for the first nine months of 2024 were approximately $13.2 million, a decrease from approximately $15.2 million in the same period of 2023[54]. - The total liabilities increased significantly to $23.3 million as of September 30, 2024, compared to $6.9 million at the end of 2023[66]. - The company incurred transaction costs and financial expenses of approximately $1.5 million related to warrants issued in a recent transaction[60]. Cash Flow and Assets - Cash usage during Q3 2024 was approximately $5.7 million, with projected cash usage for 2024 expected to be approximately $8.0 - $10.0 million, a decrease of 20% - 36% from approximately $12.5 million in 2023[53]. - Cash and cash equivalents decreased to $11.3 million as of September 30, 2024, down from $20.8 million at the end of 2023[66]. - Total current assets decreased to $25.4 million as of September 30, 2024, compared to $34.5 million at the end of 2023[66]. - The company reported cash used in operating activities of $14.5 million for the nine months ended September 30, 2024, compared to $15.7 million for the same period in 2023[68]. - The company reported a net cash provided by financing activities of $4,216,000 for the nine months ended September 30, 2024, compared to $18,299,000 in the same period of 2023[81]. Future Outlook and Strategic Initiatives - The company anticipates continued revenue growth in Q4 2024, mainly based on Casterra's forecast for seed-order supply[29]. - The company anticipates continued revenue growth for 2024, supported by ongoing investments in novel products and applications[74]. - The integration with Google Cloud is expected to enhance the company's capabilities and value proposition in the market[74]. - The company is focusing on enhancing its AI tech-engines and expanding its collaboration with Google Cloud to develop a generative AI foundation model for small molecule design[15]. - Evogene has established three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, focusing on product development in microbiomes, small molecules, and genetic elements respectively[70]. - The company is advancing its subsidiaries, including Lavie Bio and Casterra Ag, to develop microbiome-based ag-biologicals and superior castor seed varieties[62]. Fundraising Activities - The company completed a fundraising totaling $5.5 million in gross proceeds in August 2024[7].

Conference call and webcast: today, November 21, 2024, 9:00 am ETFinancial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023. In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023. The revenues in Q3 2024 are mainly based on Casterra's seed sales. The revenues in Q3 2023 included a license fee payment of $2.5 million received by Lav ...

Industry Overview - Downy mildew is a significant foliar disease affecting grapes, causing yield losses of up to 75% in key growing regions [1] - The global fungicide market is valued at over $24.5 billion in 2024 and is projected to grow to $33.27 billion by 2028, with a compound annual growth rate (CAGR) of 7.9% [2] - There is a rising public interest in environmentally friendly farming practices and concerns about fungal resistance to chemical solutions, leading to a preference for ag-biologicals like LAV321 [1] Company Insights - Lavie Bio conducted field trials for LAV321 targeting downy mildew and late blight in tomatoes, achieving an average efficacy rate exceeding 60%, comparable to traditional copper products [2] - LAV321 was developed through Lavie Bio's Biology Driven Design (BDD) platform, utilizing Evogene's MicroBoost AI technology, aimed at enhancing productivity and sustainability in Integrated Pest Management (IPM) practices [3] - CEO Amit Noam expressed satisfaction with LAV321's performance, achieving a target efficacy of 70% against downy mildew and entering the pre-commercial stage with regulatory processes to begin [4] - Lavie Bio, a subsidiary of Evogene Ltd., focuses on improving food quality and agricultural productivity through microbiome-based ag-biological products [5] Technological Advancements - Evogene employs three unique tech-engines, including MicroBoost AI, to develop life-science based products, enhancing the probability of success while reducing development time and costs [6] - The tech-engines are utilized by Evogene's subsidiaries to develop various products, including ag-biologicals by Lavie Bio [7]

Yalos® is comprised of two novel microbes that together improve early vigor, biomass, root and shoot development, and nutrient availability. It aims to improve emergence and establishment and increase farm productivity through advanced biological technologies. Currently, Yalos® is sold in North America as a seed-treatment for spring and winter wheat, durum and barley, distributed in Canada by Winfield United and in the US directly by Lavie Bio. As of spring 2025, Lavie Bio intends Yalos® to be commercially ...

The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based productsREHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to ne ...

This shipment of castor seeds, developed by Casterra and produced in Kenya, is the first to complete the entire cultivation and processing cycle in Kenya. The company is now focused on preparing upcoming shipments, which will be delivered to its customers over the coming months. Currently, approximately 700 additional hectares are sown with Casterra's premium varieties in Kenya, with harvest expected later this year and into early 2025. The castor seeds in this shipment were cultivated by experienced local ...

Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel, Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize lifescience-based product discovery and development, together with Ben-Gurion University (BGU), a re ...

Exhibit 99.1 EVOGENE LTD. AND ITS SUBSIDIARIES INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | --- | --- | |-------|------------| | | Page | | | F-2 | | | F-3 | | | F-4 - F-5 | | | F-6 - F-7 | | | F-8 - F-19 | Consolidated Interim Statements of Financial Position Consolidated Interim Statements of Profit or Loss Consolidated Interim Statements of Changes in Equity Consolidated Interim Statements of Cash Flows Notes to Consolidated Interim Financial S ...

REHOVOT, Israel, Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary ...

Financial Data and Key Metrics - Total revenues for the first six months of 2024 reached approximately $5.1 million, compared to $1.3 million in the first half of 2023, driven by Casterra's seed supply and Lavie Bio's licensing agreement [6][29] - Q2 2024 revenues were approximately $914,000, up from $654,000 in Q2 2023, primarily due to increased revenues from Lavie Bio [7][30] - Net loss for the first half of 2024 was approximately $9.8 million, a significant improvement from $14.8 million in the same period last year, driven by increased revenues and decreased operating expenses [7][34] - Projected cash usage for 2024, excluding Biomica and Lavie Bio, is approximately $8 million, a 36% decrease from $12.5 million in 2023 [7][29] Business Line Performance - **Casterra**: Received an additional purchase order of $440,000 for castor seeds, with total existing orders amounting to $8.4 million expected to be fulfilled by the end of 2024 [8][14] - **Biomica**: Preliminary Phase 1 trial results for BMC128 showed promising efficacy and safety in treating refractory cancers, with data presented at ASCO 2024 [9][16] - **Lavie Bio**: Expanded its bio-inoculant product Yalos to winter wheat, doubling its market potential, and identified over a dozen novel microbial candidates using its BDD technology platform [9][15] Market and Strategic Direction - The global castor oil market is projected to reach $1.68 billion by 2028, driven by increasing demand for sustainable and renewable resources in bio-based industries [20][22] - Casterra aims to establish itself as a leading provider of sustainable vegetable oil feedstock, particularly for the biofuel sector, leveraging its elite castor seed varieties and advanced cultivation techniques [18][21] - Evogene's AI-driven tech-engines (MicroBoost AI, ChemPass AI, GeneRator AI) are designed to optimize life science product development across various market segments, focusing on efficiency and cost-effectiveness [10][11] Management Commentary on Future Prospects - Management anticipates continued revenue growth in the second half of 2024, driven by Casterra's seed supply and Lavie Bio's product expansion [6][30] - The company is exploring the potential to expand into castor oil production, which could further enhance its market position and revenue streams [27][28] - Evogene's subsidiaries are advancing their pipelines, with significant milestones expected in Q4 2024, particularly in Lavie Bio's field trials and Biomica's clinical development [15][17] Q&A Session Summary Question: What is Casterra's current backlog for 2025, and will oil production be based in Africa or Brazil? - Casterra is working on its 2025 backlog, with details expected in the next analyst call. Oil production is under evaluation, with potential locations in both Africa and Brazil [35][36] Question: Can you provide an update on AgPlenus? - AgPlenus is focused on building a new pipeline, particularly in fungicides, and is collaborating with Bayer and Corteva. Updates are expected in the next quarter [37][38] Question: What is the trajectory of Casterra's castor seed launch in 2H 2024, and what is the current gross margin profile? - Casterra aims to fulfill $8.4 million in seed orders by the end of 2024, with a current production capacity of over 1,000 hectares. Gross margins are high, particularly in seed sales, with potential for further improvement in oil production [40][42] Question: When should we expect material revenue contribution from Yalos? - Yalos is expected to see material growth in sales by 2026, with early adoption in soybean and canola markets starting in 2025 [43][44] Question: What is Evogene's expected cash position by the end of 2024? - Assuming $8.4 million in castor seed revenues, Evogene's cash position is expected to be around $18-19 million by the end of 2024 [46][47]